Evaluation of the good tumor response of embryonal tumor with abundant neuropil and true rosettes (ETANTR)
Autor: | Gábor Benyó, Tibor Hortobágyi, Peter Hauser, Petra Mózes, László Bognár, István Peták, Katalin Hideghéty, Adrienne Cserháti, Zoltán Nagy, Katalin Bartyik, Eszter Turányi, Miklós Garami |
---|---|
Rok vydání: | 2015 |
Předmět: |
Oncology
Cancer Research medicine.medical_specialty Pathology Neuropil Neurology medicine.medical_treatment Klinikai orvostudományok 03 medical and health sciences 0302 clinical medicine Internal medicine Humans Medicine Chemotherapy Temozolomide Brain Neoplasms business.industry Orvostudományok Neoplasms Germ Cell and Embryonal Magnetic Resonance Imaging Transplantation Radiation therapy Ki-67 Antigen medicine.anatomical_structure Child Preschool 030220 oncology & carcinogenesis Female Neurology (clinical) Stem cell business Adjuvant 030217 neurology & neurosurgery medicine.drug |
Zdroj: | Journal of Neuro-Oncology. 126:99-105 |
ISSN: | 1573-7373 0167-594X |
DOI: | 10.1007/s11060-015-1938-3 |
Popis: | The embryonal tumor with abundant neuropil and true rosettes is a rare and highly malignant variant of embryonal brain tumors. It usually affects infants and young children under the age of 4 years and exhibits a very aggressive course with a dismal prognosis. For the 68 cases reported to date the mean age at diagnosis was 25.42 months (range 3-57 months). Survival data are available for 48 children (including our case): the median overall survival is 13.0 months, though 6 (9%) of the children have had a relative long survival (>30 months). The aggressive combined treatment, involving primary surgical tumor removal, adjuvant polychemotherapy, including high-dose chemotherapy with stem cell transplantation, radiotherapy and radiochemotherapy, might play an important role in the longer survival. We have performed a literature review and we present here a multimodal-treated case of a 2- year-old girl with a long survival, who was reoperated when recurrence occurred. The residual tumor demonstrated a good response to temozolomide radiochemotherapy (craniospinal axis + boost) and followed by maintenance temozolomide. The described complex aggressive treatment option might be considered for future cases of this tumor entity. |
Databáze: | OpenAIRE |
Externí odkaz: |